AM966

AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM) .

Product Specifications

CAS Number

[1228690-19-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

LPL Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/AM966.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CC1=CC=C(C2=CC=C(C3=C(NC(O[C@@H](C4=CC=CC=C4Cl)C)=O)C(C)=NO3)C=C2)C=C1

Molecular Formula

C27H23ClN2O5

Molecular Weight

490.93

Precautions

H302, H315, H319, H335

References & Citations

[1]Swaney, JS, et al. A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010 Aug;160 (7) :1699-713.|[2]Olianas MC, et al. Antidepressants activate the lysophosphatidic acid receptor LPA (1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts. Biochem Pharmacol. 2015 Jun 15;95 (4) :311-23.